CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report

Article Medicine, Research & Experimental

Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

Eric Tu et al.

Summary: Anti-PD-1 and anti-PD-L1 therapies are effective in non-small cell lung cancer (NSCLC), but less so in patients with EGFR mutations. This study found that EGFR-mutated NSCLC expressed higher levels of CD73 and were more resistant to T cell killing. Combining anti-PD-L1 and anti-CD73 therapies significantly inhibited tumor growth and increased T cell activity in EGFR-mutated NSCLC. These findings support the use of combination therapy in this patient population.

JCI INSIGHT (2022)

Add to Collection

Article Oncology

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer

Roy S. Herbst et al.

Summary: The COAST study evaluated the efficacy of durvalumab combined with other antibodies in patients with unresectable stage III non-small-cell lung cancer. The results showed that compared to durvalumab alone, the combination of durvalumab with oleclumab or monalizumab significantly improved the objective response rate and progression-free survival of patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

Xiuning Le et al.

Summary: EGFR-mutant non-small cell lung cancer exhibits an immune-inert phenotype, with the CD73/adenosine pathway identified as a potential therapeutic target for treatment enhancement.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology